We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
daniel
blackburn
d.blackburn@sheffield.ac.uk
Dr
daniel
blackburn
d.blackburn@sheffield.ac.uk
Other degenerative diseases of the nervous systemOrganic, including symptomatic, mental disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
An accurate early diagnosis of Alzheimer’s disease is crucial in order to provide support for people with dementia and their carers. Tests of memory and other higher-level processes cannot reliably diagnose people with early AD from those due to depression, strokes or other types of dementia. Brain scans can exclude other causes of memory problems (such as a tumour), but cannot make a positive diagnosis because brain shrinkage only occurs after the onset of dementia.
Changes in brain connectivity may be a useful early marker of dementia. How well the brain is connected can be measured using magnetic resonance imaging (MRI) brain scans but also with electroencephalography (EEG). EEG is more ‘patient-friendly’ as it only requires electrodes to be placed on the scalp to measure electrical activity. It is commonly used to diagnose epilepsy. EEG has been used to detect changes in connectivity in people with dementia but the methods are not sensitive enough to be used as a clinical diagnostic test. The University of Sheffield has developed new techniques using EEG to examine brain connectivity. This research will study EEG to see if subtle changes in brain-connectivity can help make a diagnosis of AD at an early stage.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Imaging;
You can take part if:
You may not be able to take part if:
- Clinical history of epilepsy or severe auditory, visual, language or motor impairment. - Moderate to severe dementia (defined by research team but we wouldn’t expect those with a mini mental state exam [MMSE] ≤ 18 to be able to participate) - Severe current mental health disorder (depression, psychosis) - Patients on sedating or antiepileptic medication
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST and funded by ALZHEIMER'S RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 18002
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
